TR201806828T4 - Gut ve hiperürisemi tedavisi. - Google Patents

Gut ve hiperürisemi tedavisi. Download PDF

Info

Publication number
TR201806828T4
TR201806828T4 TR2018/06828T TR201806828T TR201806828T4 TR 201806828 T4 TR201806828 T4 TR 201806828T4 TR 2018/06828 T TR2018/06828 T TR 2018/06828T TR 201806828 T TR201806828 T TR 201806828T TR 201806828 T4 TR201806828 T4 TR 201806828T4
Authority
TR
Turkey
Prior art keywords
gout
allopurinol
compound
acetate
levels
Prior art date
Application number
TR2018/06828T
Other languages
English (en)
Turkish (tr)
Inventor
Miner Jeffrey
D Quart Barry
Girardet Jean-Luc
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201806828(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of TR201806828T4 publication Critical patent/TR201806828T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2018/06828T 2010-06-15 2011-06-14 Gut ve hiperürisemi tedavisi. TR201806828T4 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US41144910P 2010-11-08 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US201161489420P 2011-05-24 2011-05-24

Publications (1)

Publication Number Publication Date
TR201806828T4 true TR201806828T4 (tr) 2018-06-21

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/06828T TR201806828T4 (tr) 2010-06-15 2011-06-14 Gut ve hiperürisemi tedavisi.

Country Status (19)

Country Link
US (3) US9216179B2 (enExample)
EP (1) EP2582683B1 (enExample)
JP (1) JP5964821B2 (enExample)
CA (1) CA2802407C (enExample)
CY (1) CY1120473T1 (enExample)
DK (1) DK2582683T3 (enExample)
ES (1) ES2670700T3 (enExample)
HR (1) HRP20180780T1 (enExample)
HU (1) HUE038265T2 (enExample)
LT (1) LT2582683T (enExample)
NO (1) NO2019008I1 (enExample)
PL (1) PL2582683T3 (enExample)
PT (1) PT2582683T (enExample)
RS (1) RS57275B1 (enExample)
SI (1) SI2582683T1 (enExample)
SM (1) SMT201800266T1 (enExample)
TR (1) TR201806828T4 (enExample)
WO (1) WO2011159732A1 (enExample)
ZA (1) ZA201300055B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794798C (en) 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
CA2802407C (en) * 2010-06-15 2018-01-23 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
CA2852490A1 (en) * 2011-11-03 2013-05-10 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound to reduce serum uric acid levels
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
US9969701B2 (en) 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
SG11201804100UA (en) * 2015-12-08 2018-06-28 Ardea Biosciences Inc Pharmaceutical composition comprising a potent inhibitor of urat1
US12152347B2 (en) 2018-10-26 2024-11-26 The Procter & Gamble Company Sanitary tissue product rolls
US11633076B2 (en) 2018-10-26 2023-04-25 The Procter & Gamble Company Sanitary tissue product rolls
CA3060185A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
US11447916B2 (en) 2018-10-26 2022-09-20 The Procter & Gamble Company Paper towel rolls
CN114341120A (zh) * 2019-08-21 2022-04-12 国立大学法人东京大学 Abcc11抑制剂
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE537181T1 (de) 2003-12-26 2011-12-15 Kissei Pharmaceutical Benzimidazolderivate und deren medizinische verwendungen
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2006026356A2 (en) 2004-08-25 2006-03-09 Ardea Biosciences, Inc. S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
AU2008206231A1 (en) 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CN102186832B (zh) 2008-09-04 2014-04-02 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
JP2012527475A (ja) * 2009-05-20 2012-11-08 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及び方法
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
WO2011085009A2 (en) 2010-01-08 2011-07-14 Ardea Biosciences, Inc. Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
CA2794798C (en) * 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
CA2802407C (en) * 2010-06-15 2018-01-23 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
WO2012000103A1 (en) * 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
EP2627331A4 (en) * 2010-10-15 2014-03-12 Ardea Biosciences Inc METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
RS55667B1 (sr) 2010-12-30 2017-06-30 Ardea Biosciences Inc Polimorfne forme 2-(5-bromo-4-(4-cilkopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio) sirćetne kiseline i njihova upotreba
CA2837080C (en) 2011-05-24 2017-01-24 Ardea Biosciences, Inc. Hypertension and hyperuricemia

Also Published As

Publication number Publication date
CA2802407C (en) 2018-01-23
US20160143889A1 (en) 2016-05-26
LT2582683T (lt) 2018-06-11
US20130178484A1 (en) 2013-07-11
WO2011159732A1 (en) 2011-12-22
SI2582683T1 (en) 2018-07-31
EP2582683A4 (en) 2014-04-30
ZA201300055B (en) 2018-05-30
PT2582683T (pt) 2018-05-25
US9216179B2 (en) 2015-12-22
JP2013528650A (ja) 2013-07-11
RS57275B1 (sr) 2018-08-31
HRP20180780T1 (hr) 2018-07-13
HUE038265T2 (hu) 2018-10-29
PL2582683T3 (pl) 2018-08-31
NO2019008I1 (no) 2019-02-19
SMT201800266T1 (it) 2018-07-17
CY1120473T1 (el) 2019-07-10
US20190015392A1 (en) 2019-01-17
DK2582683T3 (en) 2018-06-06
EP2582683A1 (en) 2013-04-24
EP2582683B1 (en) 2018-03-21
ES2670700T3 (es) 2018-05-31
JP5964821B2 (ja) 2016-08-03
CA2802407A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
DK2582683T3 (en) TREATMENT OF Gout and Hyperuricemia
CA2794798C (en) Treatment of gout
US9421208B2 (en) Methods for the treatment of solid tumors
CN104519887B (zh) 包含B‑Raf抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合
US20160129003A1 (en) Pharmaceutical Combinations
AU2021382148A1 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
WO2010031061A1 (en) Methods of treatment of hyperuricemia and associated disease states
JP2022501394A (ja) Ｍｄｍ２阻害剤の医薬組成物、並びに疾患を予防及び／又は治療するためのその使用
US20170224670A1 (en) Drug Combination to Treat Melanoma
JP2026048915A (ja) プレカリクレイン関連の状態を治療及び予防するための組成物及び方法
US20110251134A1 (en) Combination of (a) a dna toposomerase inhibitor and (b) an iap inhibitor
WO2015022657A1 (en) Pharmaceutical combinations
EP3265075B1 (en) Roneparstat combined therapy of multiple myeloma
WO2024102968A1 (en) Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap)
WO2024175106A1 (zh) Pd-l1小分子抑制剂与抗体的药物组合及其应用
TW202604485A (zh) 患有肝損傷患者肝疾病之治療
US20160136249A1 (en) Novel compositions for the treament of cancer